Your browser doesn't support javascript.
loading
Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.
Moorthy, Ganga S; Greenberg, Rachel G; Hornik, Chi D; Cassino, Cara; Ghahramani, Parviz; Kumar, Karan R; Fowler, Vance G; Cohen-Wolkowiez, Michael.
Afiliação
  • Moorthy GS; Duke University Medical Center, Durham, North Carolina, USA.
  • Greenberg RG; Duke University Medical Center, Durham, North Carolina, USA.
  • Hornik CD; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Cassino C; Duke University Medical Center, Durham, North Carolina, USA.
  • Ghahramani P; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Kumar KR; ContraFect Corporation, Yonkers, New York, USA.
  • Fowler VG; Inncelerex, Weehawken, New Jersey, USA.
  • Cohen-Wolkowiez M; Duke University Medical Center, Durham, North Carolina, USA.
Clin Infect Dis ; 75(2): 338-341, 2022 08 25.
Article em En | MEDLINE | ID: mdl-34894129
Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics. Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Staphylococcus aureus Resistente à Meticilina Limite: Child / Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Estafilocócicas / Staphylococcus aureus Resistente à Meticilina Limite: Child / Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article